Infusion preparation

Patent metadata

Field	Value
Publication number	US-9884149-B2
Application number	US-201715627783-A
Country	US
Kind code	B2
Filing date	Jun 20, 2017
Priority date	Nov 29, 2010
Publication date	Feb 6, 2018
Grant date	Feb 6, 2018

Abstract

An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0, the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5, and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition.

First claim

The invention claimed is:

1. An infusion preparation comprising two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion comprising a sugar, a fat emulsion, vitamin B6 and folic acid;
a second chamber contains a second-chamber infusion comprising an amino acid, an electrolyte and vitamin B2;
vitamin B6 and folic acid are placed in the first chamber only,
vitamin B2 is placed in the second chamber only,
the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0;
the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5;
and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition.

2. The infusion preparation according to claim 1 wherein the first-chamber infusion has a pH of 4.5 to 6.5, and the second-chamber infusion has a pH of 6.0 to 7.4.

3. The infusion preparation according to claim 1 , wherein the volume ratio of the first-chamber infusion to the second-chamber infusion is 3:2 to 3:5.

4. The infusion preparation according to claim 2 , wherein the volume ratio of the first-chamber infusion to the second-chamber infusion is 3:2 to 3:5.

5. The infusion preparation according to claim 1 , wherein the first chamber further contains vitamin B1.

6. The infusion preparation according to claim 2 , wherein the first chamber further contains vitamin B1.

7. The infusion preparation according to claim 3 , wherein the first chamber further contains vitamin B1.

8. The infusion preparation according to claim 4 , wherein the first chamber further contains vitamin B1.

Assignees

• Otsuka Pharma Factory Inc

Inventors

• Tani Seiji
• Mitsumoto Yasuhiro

Classifications

• A61P7/08

  Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A61K31/685

  one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin · CPC title

• A23L33/175

  Amino acids · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title